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From control to elimination 
through mass drug 
administration
The London Declaration on 
Neglected Tropical Diseases of 
January 2012 called for sustained 
efforts to expand and extend 
drug access programmes to 
ensure the necessary supply of 
drugs and other interventions 
to help control human 
onchocerciasis (river blindness). 
The African Programme for 
Onchocerciasis Control (APOC) 
has extended its mandate, 
under the new Programme for 
the Elimination of Neglected 
Diseases in Africa (PENDA) 
to begin in 2016, with a new 
aim of eliminating Onchocerca 
volvulus, the causative agent of 
onchocerciasis, by 2025. 
APOC’s work is predicated 
on sole use of mass drug 
administration (MDA) of 
ivermectin (MectizanTM). Moving 
from control to elimination using 
MDA of ivermectin alone will be 
a challenge, and this strategy 
may not be sufficient to achieve 
onchocerciasis elimination. 
A known deficiency of MDA 
programming is the fact that 
ivermectin cannot be used in 
areas where onchocerciasis and 
loiasis are co-endemic due to the 
risk of severe adverse reactions 
following drug treatment.  It 
is estimated that 12 million 
people live in such high risk 
areas in central Africa (Figure 1) 
and are potentially affected by 
this contraindication. In these 
areas, communities often do not 
receive supportive treatment; 
onchocerciasis transmission rates 
remain high; and, reintroduction 
of the infection to neighbouring 
communities from which the 
disease has been eliminated is an ongoing threat. 
Additionally, the potential widespread emergence of drug-resistant 
O volvulus poses a threat to the long-term effectiveness of using 
ivermectin alone in all areas. In some foci, microfilariae are 
reappearing in the skin following ivermectin treatment at a faster rate 
than anticipated, and this may be indicative of development of drug 
resistance.
Successful elimination of onchocerciasis will ultimately require 
irreversible reductions in O volvulus microfilariae production by 30-
35% following each annual round of ivermectin treatment.  However, 
there is great uncertainty around such estimates.  Disease modelling 
studies suggest that, depending on compliance and levels of parasite 
transmission, it may not be possible to achieve onchocerciasis 
elimination even after 50 years of annual ivermectin treatments, thereby 
necessitating the adoption of biannual treatments. This would place 
additional logistical and financial challenges on MDA programmes as 
well as potentially increasing the rate of emergence of drug resistance. 
These models recognize the fact that ivermectin does not kill the (long-
lived) adult worms and, in areas of high transmission, microfilariae 
reappear in the skin during the inter-treatment period. 
Development of new tools (such as drugs, diagnostics and 
vaccines) will be required to ensure onchocerciasis elimination 
and remove the risk of reintroduction of the infection to areas 
where elimination may have been achieved. Such new tools would 
potentiate or enhance the efficiency of ivermectin treatments and 
address the identified deficiencies of the current MDA 
programming.
New supportive health intervention technologies, including a vaccine, may be required in order to 
achieve onchocerciasis (river blindness) elimination targets. A new Trans-Atlantic partnership, the 
Onchocerciasis Vaccine for Africa (TOVA) Initiative, has been established to develop and test an 
onchocerciasis vaccine for Africa.  
Figure 1 Onchocerciasis and loiasis high risk areas
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Vaccine as a new tool to aid in elimination
The Onchocerciasis Vaccine for Africa (TOVA) Initiative has been launched as a response to the London 
Declaration on Neglected Tropical Diseases; and, the scientific and technical demands for new tools to 
complement ivermectin MDA to ensure elimination of onchocerciasis from Africa.
 
TOVA has its origins in the river blindness (onchocerciasis) vaccine program of the Edna McConnell Clark 
Foundation (EMCF) that contributed $21.6 million between 1985 and 1999.
This investment focused on:
• development of experimental animal models for screening candidate vaccine antigens and analysis of  
 mechanisms evoked by immunization with protective recombinant vaccine antigens
•  immunological studies in animals and in humans
•  identification of protective antigens
•  increased understanding of the epidemiology and pathology of river blindness
When the programme ended, the work of African, American and European laboratories had developed 
three animal models, identified a portfolio of 15 O volvulus vaccine candidates including eight that were 
tested in the O ochengi bovine model, and obtained proof-of-principle of vaccination against infection.
The impetus given by EMCF was carried forward by the European Union through its Directorate-General 
for Research and Innovation (FP7, E PIAF, Enhanced Protective Immunity Against Filariasis, coordinated 
by Professor David W Taylor), and by the US NIH National Institute of Allergy and Infectious Diseases (The 
development of a recombinant vaccine against human onchocerciasis headed by Dr Sara Lustigman).
The work of these programmes 
(Figure 2) has identified three 
candidate vaccine antigens that 
have proven to be efficacious in 
three different filarial animal model 
systems and in three independent 
laboratories (Table 1).
The Onchocerciasis Vaccine for 
Africa (TOVA) Initiative brings 
established US and African-
European consortia together 
with the best practice of product 
development from the Sabin 
Vaccine Institute and Texas 
Children’s Hospital Center for 
Vaccine Development, Sabin PDP 
(Professors Peter Hotez and Maria 
Elena Bottazzi), and mathematical 
modelling from Imperial College 
London (Professor María-Gloria 
Basáñez).
The demand
Figure 2, Progress towards a vaccine against River Blindness 
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TOVA is here 
Protecting children, reducing morbidity and transmission
Our goal is production and testing of a river blindness vaccine to Phase I clinical trials in 2017 and 
Phase II efficacy trials by 2020.
It is envisaged that the onchocerciasis vaccine will be used initially to protect vulnerable children 
(<5 years of age) living in loiasis co-endemic areas. The vaccine will reduce adult worm burden and 
fecundity with consequential reduction in pathology associated with microfilariae (Figure 3). In addition, 
a vaccine will find use in ongoing ivermectin MDA areas and contribute to reduction in transmission 
rates; and, will protect areas where local elimination may have been achieved. 
Table 1, Onchocerciasis (river blindness) vaccine candidates
Figure 3, The vaccine targets and objectives
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The vaccine
Modelling analyses have shown that an onchocerciasis vaccine will have a substantial impact in a range of 
endemicity scenarios (Figure 4) and will markedly reduce microfilarial load in those under 20 years of age. 
This has important implications as studies have highlighted the increased risk of developing onchocerciasis- 
related morbidity and mortality in individuals who acquire heavy infections in early life.
It is clear that a vaccine would have a beneficial impact by reducing onchocerciasis-related disease burden 
in these populations. Furthermore, a vaccine could markedly decrease the chance of recrudescence of 
onchocerciasis in areas where MDA treatment has stopped.
The impact of vaccination
Figure 4, A vaccine will be of greatest benefit to children and young adults
Added value
 
A vaccine would protect the substantial investments made by present and past onchocerciasis control 
programmes (together, the Onchocerciasis Control Programme in West Africa (OCP) and APOC have 
cost over US$1 billion), by reducing the chance of disease recrudescence and the possible spread of 
ivermectin resistance.
Turner et al (unpublished)
These models are based on a vaccination programme that targets children between 1 and 5 years old 
during its first year, and 1 year old infants during subsequent years. An initial vaccine efficacy of 50% 
against the infecting L3 larvae and a 90% reduction of skin microfilarial load is assumed giving a mean 
duration of any protective effects of the vaccine of 20 years with an 80% coverage of vaccination.
0
0 20 40 60 80
Age
Co
nt
rib
ut
io
n 
to
 in
fe
ct
io
n 
bu
rd
en
*
0
0 20 40 60 80
Age
0
0 20 40 60 80
Age
Mesoendemic Hyperendemic Highly Hyperendemic
Overall mean mf load decreases by 30% but maximum impact on infection burden in young adults
No Intervention
15 years of vaccination
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Turner et al. (unpublished) 
*age-specic mean mf load multiplied by the probability of being in each age group 
The way forward for vaccine development 
TOVA Initiative has set its goal to take at least one vaccine candidate to Phase I trials by 2017 and Phase II 
trials by 2020. To do this the following tasks have been identified:
1. Mathematical modelling of vaccine efficacy and delivery, as well as cost-effectiveness.
2. Systems analysis to identify specific molecular interactions between parasite antigens and host   
 immune systems to assist with formulation of the vaccine for greatest efficacy and importantly, to avoid  
 any interaction that may lead to adverse reactions, including allergic and physiological responses.
3. Optimization of immunization strategies using the three filarial small animal models.
4. Efficacy trials using the O ochengi cattle model under conditions of natural exposure. 
5. Process development for human recombinant vaccine production or synthetic vaccines, including   
 formulation, assay development, quality control and stability.
6. Technology transfer for cGMP manufacturing of vaccines.
7. GLP toxicology testing of vaccines.
8. Regulatory filing.
9. Phase I, first-in-human safety trials in developed and in endemic countries.
10. Assessment of immune responses of children up to 9 years age who are exposed to O volvulus   
 infections in preparation for phase II trials.
What is needed to achieve our mission?
Table 2, Milestones en route to an onchocerciasis vaccine
Activity 2014 2015 2016 2017 2018 2019 2020 
1 Mathematical modelling 
2 Host and parasite systems analysis 
for immune correlates and 
avoidance of pathology 
3 Optimization of immunization 
strategies small animal models 
4 Efficacy trials using the O ochengi
cattle model 
5 Process development for human 
recombinant vaccine production 
6 Current GMP Manufacturing of 
vaccines 
7 GLP Toxicology testing  
8 Regulatory filing  
9 Phase I first-in-human safety trials  
10 Assessment of immune responses 
of children  
  
Colours identify different work packages. The relative activity of individual work packages are indicated 
by circle area.
The approach
Table 3, Target product profile of a prophylactic onchocerciasis vaccine
 
Item Desired target 
Indication A vaccine to protect against infection with infective (L3) 
larvae and to reduce adult worm burden and microfiladermia 
for the purpose of reducing morbidity and transmission.   
Target Population Children < 5 years. 
Route of Administration Intramuscular injection. 
Product Presentation Single-dose vials; 0.5 ml volume of delivery. 
Dosage Schedule Maximum of 3 immunizations given 4 weeks apart. 
Warnings and Precautions/Pregnancy  
and Lactation 
Mild to moderate local injection site reactions such as 
erythema, edema and pain, the character, frequency, and 
severity of which is similar to licensed recombinant protein 
vaccines. Less than 0.01% risk of urticaria and other 
systemic allergic reactions. Incidence of serious adverse 
reactions no more than licensed comparator vaccines. 
Expected Efficacy >50% efficacy at preventing establishment of incoming 
worms; >90% reduction of microfilariae (based on current 
animal model results).  
Co-administration All doses may be co-administered and/or used with other 
infant immunization programmes. 
Shelf-Life 4 Years. 
Storage Refrigeration between 2 to 8 degrees Celsius. Cannot be 
frozen. Can be out of refrigeration (at temperatures up to 25 
degrees) for up to 72 hours. 
Product Registration Licensure by the Food and Drug Administration and/or the 
European Medicine Agency. 
Target price Less than $10 per dose for use in low- and middle-income 
countries. 
TOVA Initiative represents a collaborative effort between a team of experienced investigators who have 
been working together on river blindness for 30 years. These investigators are supported by young 
scientists with expertise ranging from mathematical modelling, through immunology, proteomics and 
genomics, vaccinology and product development to clinical practice. TOVA Initiative will adopt the Product 
Development Partnership (PDP) approach used by the Sabin PDP for accelerating the development of new 
vaccines for global health. 
TOVA: who we are
Name Participant’s organization, country Role in the Partnership
The partners from Africa
Professor Samuel Wanji University of Buea, Cameroon Human studies in Cameroon 
 Research Foundation in Tropical Disease  
 and Environment 
 
Dr Vincent Tanya Cameroon Academy of Sciences Screening vaccine candidates in the 
  O ochengi cow model
 
Dr Alex Debrah Kwame Nkrumah University, Ghana Human studies in Ghana 
The partners from Europe
Professor David W Taylor University of Edinburgh, UK  Co-ordinator of the EU consortium.  
  Host gene expression profile analysis.  
  Vaccine development and human   
  studies in Cameroon
 
Dr Ben Makepeace University of Liverpool, UK Proteomic and genomic analyses and  
Professor Jonathan Wastling  vaccine development. Screening   
  vaccine candidates in the O ochengi   
  cattle model
 
Dr Simon Babayan University of Glasgow, UK Filarial immunology, vaccine  
  development and screening vaccine   
  candidates in the L sigmodontis   
  mouse model
 
Dr Coralie Martin Muséum National d’Histoire Naturelle, Screening vaccine candidates in the L 
 Paris, France sigmodontis mouse model. Host   
  gene expression profile analysis 
Professor Achim Hoerauf University Hospital of Bonn, Germany  Immunology of filarial infections and 
Dr Sabine Specht  human studies in Ghana.  
  Host gene expression profile analysis   
 
Professor María Gloria Basáñez Imperial College London, UK Mathematical modelling and  
  cost-effectiveness
The partners from USA
Dr Sara Lustigman New York Blood Center, NYC, USA Program Director of the NIH funded   
  consortium. Human studies in   
  Cameroon, characterization of vaccine  
  candidates
Professor David Abraham Thomas Jefferson University, Philadelphia,  Screening vaccine candidates in the  
 PA, USA O volvulus mouse model 
 
Professor Thomas Klei Louisiana State University, Baton Rouge,  Screening vaccine candidates in the
 LA, USA B malayi-jird model
 
Professor Maria Elena Bottazi The Sabin Vaccine Institute and Texas Product development, technology 
Professor Peter Hotez Children’s Hospital Center for Vaccine transfer for cGMP manufacture and 
 Development, Houston, TX, USA GLP toxicology testing, regulatory 
  filing, early stage clinical testing
Table 4, TOVA Partners 
TOVA is an unincorporated affiliation of the institutions listed in Table 4 that are working collaboratively to meet the 
challenges of developing a vaccine against river blindness.
TOVA: where we are
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